Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy

Figure 1

A screen of Selleck drug library approved by FDA identified TM having anti-BC activity. (a) A cell viability screening identified that TM had anti-BC activity among the compounds from the Selleck drug library approved by the FDA. (b) The linear graph of IC50 values in BC cells according to the CCK8 assay. (c) The chemical structure of TM.

(a)

(b)

(c)